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Adverse events in utero are associated with the occurrence of chronic diseases in adulthood. We previously demonstrated in mice
that perinatal hypoxia resulted in altered pulmonary circulation in adulthood, with a decreased endothelium-dependent relaxation
of pulmonary arteries, associated with long-term alterations in the nitric oxide (NO)/cyclic GMP pathway. The present study
investigated whether inhaled NO (iNO) administered simultaneously to perinatal hypoxia could have potential beneficial effects
on the adult pulmonary circulation. Indeed, iNO is the therapy of choice in humans presenting neonatal pulmonary hypertension.
Long-term effects of neonatal iNO therapy on adult pulmonary circulation have not yet been investigated. Pregnant mice were
placed in hypoxia (13% O
2
) with simultaneous administration of iNO 5 days before delivery until 5 days after birth. Pups were then
raised in normoxia until adulthood. Perinatal iNO administration completely restored acetylcholine-induced relaxation, as well as
endothelial nitric oxide synthase protein content, in isolated pulmonary arteries of adult mice born in hypoxia. Right ventricular
hypertrophy observed in old mice born in hypoxia compared to controls was also prevented by perinatal iNO treatment.Therefore,
simultaneous administration of iNO during perinatal hypoxic exposure seems able to prevent adverse effects of perinatal hypoxia
on the adult pulmonary circulation.
1. Introduction
Numerous epidemiological studies have associated adverse
events occurring in utero, like limitation of nutrients or
oxygen supply, with an increased risk to develop chronic
diseases in adulthood, including coronary artery disease,
systemic hypertension, stroke, and noninsulin-dependent
diabetes mellitus [1]. Therefore, an insult occurring in the
perinatal period, namely, during late gestation and the first
days of extrauterine life, may result in a definitive imprint
predisposing to a pathological response later in life, leading
to “programmed” diseases. However, cellular and molecu-
lar mechanisms of the programming process are not yet
elucidated [2, 3]. In particular, chronic pulmonary vascular
diseases and abnormal pulmonary vascular reactivity in
adulthood may be associated with a hypoxic insult occurring
around birth [4–8]. Humans and animals born in hypoxic
conditions, or presenting neonatal pulmonary hypertension,
show later in life an exaggerated pulmonary hypertensive
response following a reexposure to hypoxia [7, 9–13]. The
cellular and molecular mechanisms involved in the dysreg-
ulation of adult pulmonary vasomotor tone secondary to a
transient perinatal insult remain incompletely understood.
The fetal pulmonary circulation is characterized by low
perfusion and high vascular resistances, which need to
rapidly fall at birth to allow pulmonary blood flow to increase
nearly 10-fold [14, 15]. Pulmonary vascular tone is regulated
by a complex and intricate group of mechanisms [16, 17],
including the nitric oxide/cyclic guanosine monophosphate
(NO/cGMP) signaling pathway, which plays a key role
in establishing relaxation of the pulmonary vessels during
neonatal transition as well as later in life [18, 19]. Sometimes,
the normal decrease in pulmonary vascular resistances and
increase in pulmonary blood flow do not occur, resulting in
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persistent pulmonary hypertension of the newborn (PPHN).
PPHN is a severe neonatal complication, associated with
a high mortality and morbidity. Prevalence of PPHN is
estimated at 1.9 per 1000 live births and mortality ranges
from 4 to 33% [20]. This pathology represents 1 to 4% of
the admissions in a neonatal intensive care unit [21, 22] and
requires intensive therapy including supplemental oxygen
and pulmonary vasodilators [23]. InhaledNO (iNO) has been
proposed as a “selective” pulmonary vasodilator since it acts
directly on pulmonary vascular cells and is then inactivated
in the bloodstream. Inhaled NO is now recognized as the
therapy of choice for term newborns with a PPHN [24]. Most
neonates who respond to this treatment will recover within a
week and then develop normally. However, long-term effects
of neonatal iNO therapy on adult lung vascular reactivity have
not yet been investigated.
Adult pulmonary hypertension is also a severe disease
of various origins, affecting life expectancy and quality of
life [25], whose treatment is still a challenge and prognosis
remains poor [26]. Pulmonary hypertension is related to an
abnormal reactivity of the pulmonary vasculature resulting
in lower perfusion of the lung and hypoxemia. Abnormal
development of regulatory mechanisms of the pulmonary
circulation in the perinatal period could be associated with
an altered regulation of the adult pulmonary circulation.
We have previously established a murine experimental
model in order to study the long-lasting effects of a transient
exposure to hypoxia in the perinatal period [13, 27–29].
Pregnant mice were placed in hypoxic conditions (13% O
2
)
5 days before delivery and left with their litter for 5 days after
birth. Pupswere then bred in normoxia until adulthoodwhen
studied.We first demonstrated that the relaxation induced by
the endothelium-dependent agent acetylcholine (ACh) in the
adult main pulmonary artery (PA) was completely mediated
by endothelial nitric oxide synthase (eNOS) [28]. Our further
studies showed that a transient hypoxic insult in the perinatal
period resulted in altered regulation of pulmonary vascular
tone in adulthood [13, 27, 29]. Adults born in hypoxia
displayed an increase in right ventricular pressure, suggesting
a higher resistance state in the pulmonary circulation, and an
increased sensitivity to acute hypoxia compared to controls
[13]. Moreover, perinatal hypoxia dramatically decreased
endothelium-dependent relaxation induced by ACh in adult
female pulmonary arteries [13]. This alteration of adult pul-
monary circulation was associated with long-term alterations
in the NO/cGMP signaling pathway, in particular muscarinic
receptors and phosphodiesterases, and with a marked reduc-
tion in eNOS protein content in isolated pulmonary arteries
from adult females born in hypoxic conditions compared
to mice born in normoxia [13]. This could contribute to
the observed decrease in ACh-mediated relaxation following
perinatal hypoxia.
As iNO is actually the therapy of choice in humans
presenting neonatal pulmonary hypertension, we decided
to investigate in our murine experimental model whether
iNO administered simultaneously to perinatal hypoxia could
have potential beneficial effects on the adult pulmonary
circulation.
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Figure 1: Experimental design. C57BL/6 pregnant mice were
exposed from 5 days before delivery until 5 days after birth either
to normoxia, hypoxia, or hypoxia with simultaneous administration
of inhaled NO (iNO). Pups were then raised in normoxia until
adulthood. Mice were studied as young adults (5-6 months) or old
adults (12–15 months).
Effects of concomitant perinatal exposure to iNO and
hypoxiawere compared to those of perinatal hypoxia alone by
investigation of ACh-induced relaxation and eNOS protein
content in isolated pulmonary arteries, completed by anatom-
ical data in young and old adult females.
In our murine experimental model, perinatal hypoxia
triggered greater alterations in endothelium-dependent
relaxation and the NO/cGMP pathway in adult females than
adult males (unpublished data). Our previous manuscript
[13] was therefore focused on alterations occurring in the
pulmonary circulation of adult females. The present report
was consequently also limited to the effects of iNO in females.
The results obtained in mice exposed to perinatal hypoxia
and iNO were directly compared to the corresponding
data we previously published for mice born in normoxia or
hypoxia alone [13], in particular for ACh-induced relaxation
and anatomical data. Indeed, the present study was the
direct continuation of our previous work in which we used
exactly the same experimental model [13]. As all procedures
were similar between both studies, we did not repeat the
experiments performed inmice born in normoxia or hypoxia
alone and therefore some data of the referred article [13] are
shown in the present paper to better highlight the beneficial
effects of iNO therapy compared to hypoxia alone.
2. Methods
2.1. Murine Model of Perinatal Hypoxia. All experimental
procedures were approved and carried out in accordance
with the Swiss Veterinarian Animal Care Office. C57BL/6
pregnant mice were purchased from Harlan (Horst, The
Netherlands). They were all fed ad libitum and exposed to
day-night cycles. Perinatal hypoxia was induced as previously
described [13, 27] (Figure 1). Pregnant mice were placed in
hypoxic conditions (13% O
2
) 5 days before delivery and left
under hypoxia with their litter for 5 days after birth. Pups
were then raised in normoxia (21% O
2
) until adulthood.
Pups born and grown in normoxic conditions were used as
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controls. Female mice were studied as adults before week 25
(young females) or after week 50 (old females).
2.2. Perinatal Exposure to iNO. Pregnant mice were placed
in an atmosphere containing 13%O
2
and 10 ppm gaseous NO
for 10 days, more exactly for 5 days before delivery and 5 days
after birth (Figure 1). Pups were then raised in normoxia (21%
O
2
) until adulthood when studied.
Inhaled NO was administered using the SONIMIX appa-
ratus (LNIndustries, Geneva, Switzerland), which has been
adapted to allow injection of gaseous mixtures containing
oxygen, nitrogen, and NO according to the preset relative
concentrations.The applied concentration of gaseousNOwas
half the concentration currently used in clinical practice to
treat human newborns with pulmonary hypertension. NO
concentration in the box was monitored using a NO sensor
(SensorNox, SensorMedics).
2.3. Anatomical Data. Bodyweightwasmeasured 5 days after
birth. Number of alive pups was recorded at the end of the
perinatal exposure to normoxia, hypoxia, or hypoxia plus
iNO.
In adults, the heart was dissected with removal of the
auricles and separation of the right ventricle (RV) and the
left ventricle plus septum (LV + S). The RV/(LV + S) ratio
was calculated and used as an index of right ventricular
hypertrophy, which is a direct consequence of increased pul-
monary vascular resistances present in pulmonary vascular
pathologies.
2.4. Vascular Reactivity Studies. The vascular reactivity of
pulmonary arteries was investigated by isolated vessel tension
studies, as previously described [13]. Briefly, adult mice were
administered a lethal dose of pentobarbital (1 g/kg intraperi-
toneal) and the main pulmonary artery was immediately
harvested. The vessel ring was suspended in organ chamber
filled with 10mL of modified Krebs-Ringer bicarbonate
solution (mM: 118.3 NaCl, 4.7 KCl, 2.5 CaCl
2
, 1.2 MgSO
4
,
1.2 KH
2
PO
4
, 25.0 NaHCO
3
, and 11.1 glucose) maintained
at 37∘C and aerated with 95% O
2
-5% CO
2
(pH 7.4) [13,
27]. Vessels were brought to their optimal resting tension
after 2 stretches of 0.5 g. After equilibration, indomethacin
(10−5M) was added in order to exclude possible interference
of endogenous prostanoids.The vessels were then contracted
with phenylephrine (10−5M) and pharmacological response
of isolated pulmonary arteries was evaluated in the presence
of increasing concentrations of the endothelium-dependent
relaxing agent ACh. Change in tension induced by the
vasodilator was expressed as percent of the initial contraction
induced by phenylephrine.
2.5. Western Blotting Analysis of Protein Expression. Specific
protein content in pulmonary arteries was investigated by
western blotting analysis as previously described [13]. Briefly,
each flash-frozenmain PAwas crushed in a cryogenicmortar
and homogenized in 26𝜇L of lysis buffer (50mM HEPES,
1mMEDTA, 1mMEGTA, 10% glycerol, 1mMDTT, 5 𝜇g/mL
pepstatin, 3𝜇g/mL aprotinin, 10 𝜇g/mL leupeptin, 0.1mM
4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride,
1mM sodium vanadate, 50mM NaF, and 20mM 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate).
After a 45min incubation on ice, the homogenates were
centrifuged for 10min at 3000×g at 4∘C. Five 𝜇L of each
supernatant was diluted in Laemmli buffer and heated for
5min at 95∘C before loading on a 7.5% polyacrylamide gel.
Proteins were fractioned by SDS-PAGE (35min at 200V)
and transferred to PVDF membrane (Bio-Rad, Hercules,
CA, USA) during 2 h at 100V. Blots were blocked overnight
at 4∘C in Tris-buffered saline plus 0.05% Tween 20 (TBS-T)
containing 5% nonfat dry milk. All washing steps were
performed using TBS-T. Membranes were immunoblotted
for 1 h at room temperature using specific antibodies targeted
against eNOS (BDTransduction Laboratories, Franklin Lake,
NJ, USA), or 𝛽-actin (Sigma), diluted 1 : 200 (for eNOS),
or 1 : 250 (for 𝛽-actin) in TBS-T containing 5% nonfat
dry milk. Blots were then incubated with ECL horseradish
peroxidase-linked anti-mouse antibody (for eNOS detection)
or anti-rabbit antibody (for𝛽-actin) (AmershamBiosciences,
Buckinghamshire, UK), diluted 1 : 10,000 in TBS-T. Finally,
specific proteins were detected by chemiluminescence using
the SuperSignal West Pico Chemiluminescent Substrate
(Pierce) and exposition to X-ray film. Expression of eNOS
was quantified using the UN-SCAN-IT gel software (Silk
Scientific, Orem, UT, USA) and normalized to 𝛽-actin
content. Relative protein content in homogenates of mice
born in hypoxia was reported to the content measured in
controls.
2.6. Drugs. Unless otherwise specified, all drugs were pur-
chased from Sigma (St. Louis, MO). Indomethacin was
prepared in equal molar Na
2
CO
3
[30]. The other drugs were
prepared using distilled water.
2.7. Data Analyses. Statistical analyses were performed using
InStat 3.0 or Prism 4.0 (GraphPad Software, San Diego, CA).
Data are expressed as mean ± SEM, and 𝑛 represents the
number of animals per group. Unless otherwise mentioned,
the influence of perinatal exposure to hypoxia and/or iNO
on the studied parameters was analyzed using the Mann-
Whitney test. Two-way ANOVA was performed to compare
the dose-response curves in isolated vessel tension studies.
The difference was considered statistically significant when
𝑃 < 0.05.
3. Results
3.1. Neonatal Data. Table 1 summarizes body weight and
number of pups per litter recorded at the end of the 10-
day exposure to normoxia, hypoxia, or hypoxia plus iNO.
Body weight was significantly reduced in 5-day-old pups
born in hypoxia, with or without iNO, compared to controls.
The number of alive pups per litter was also significantly
lower after perinatal exposure to hypoxia, in the absence
or presence of iNO, compared to normoxia. Although the
number of alive pups appeared to be higher in litters exposed
4 BioMed Research International
Table 1: Body weight and number of alive pups per litter at 5 days after birth.
5-day-old mice Control
𝑛 = 119
Perinatal hypoxia
𝑛 = 46
Perinatal hypoxia + iNO
𝑛 = 98
Body weight (g) 2.90 ± 0.03 2.60 ± 0.07∗ 2.72 ± 0.04∗
Pups per litter 7.0 (4–10) 4.5 (3–7)∗ 6.0 (3–7)∗
Body weight and number of alive pups per litter were recorded at the end of the perinatal exposure to normoxia (control), hypoxia, or hypoxia and inhaled NO
(iNO). Results are expressed as mean ± SEM for body weight and median (range) for the number of pups per litter; 𝑛 corresponds to the number of animals
studied in each group. ∗Significant difference compared to controls (𝑃 < 0.05, using the nonparametric Mann-Whitney test).
Table 2: Anatomical data.
5-6-month-old mice Control
𝑛 = 25
Perinatal hypoxia
𝑛 = 20
Perinatal hypoxia + iNO
𝑛 = 13
Body weight (g) 22.83 ± 0.39 22.63 ± 0.36 23.68 ± 0.41
Heart weight (g) 0.100 ± 0.002 0.097 ± 0.001 0.093 ± 0.002∗†
Heart/body ratio 0.0044 ± 0.0001 0.0043 ± 0.0001 0.0039 ± 0.0001∗†
RV weight (g) 0.0230 ± 0.0005 0.0227 ± 0.0006 0.0205 ± 0.0006∗†
(LV + S) weight (g) 0.0771 ± 0.0015 0.0745 ± 0.0009 0.0721 ± 0.0013∗
Ratio RV/(LV + S) 0.300 ± 0.006 0.304 ± 0.008 0.285 ± 0.010
12–15-month-old mice Control
𝑛 = 11
Perinatal hypoxia
𝑛 = 15
Perinatal hypoxia + iNO
𝑛 = 17
Body weight (g) 26.84 ± 1.10 28.15 ± 0.92 27.32 ± 0.64
Heart weight (g) 0.107 ± 0.003 0.107 ± 0.002 0.109 ± 0.002
Heart/body ratio 0.0040 ± 0.0002 0.0038 ± 0.0001 0.0040 ± 0.0001
RV weight (g) 0.0231 ± 0.0010 0.0252 ± 0.0004 0.0231 ± 0.0005†
(LV + S) weight (g) 0.0835 ± 0.0023 0.0821 ± 0.0018 0.0855 ± 0.0015
Ratio RV/(LV + S) 0.276 ± 0.009 0.309 ± 0.008∗ 0.271 ± 0.004†
Body weight was measured after sacrifice of adult mice. Heart weight corresponds to the sum of the wet weights of the right ventricle (RV) and of the left
ventricle plus septum (LV + S). The RV/(LV + S) ratio is the ratio between the weights of RV and LV + S, used as an index of right ventricular hypertrophy.
Results are expressed as mean ± SEM; 𝑛 corresponds to the number of animals in each group. ∗Significant difference compared to controls and †significant
difference between mice exposed to perinatal hypoxia plus iNO and mice with perinatal hypoxia alone (𝑃 < 0.05, using the Mann-Whitney test). Data related
to 5-6-month-old mice born in normoxia (Ctr) or in hypoxia (PH) were previously published [13].
to perinatal hypoxia and iNO than in those with perinatal
hypoxia alone, the difference was not statistically significant.
3.2. Anatomical Data in Adults. Table 2 summarizes anatom-
ical data measured in adult females after sacrifice.
In young females (5-6-month-old mice), perinatal
hypoxia did not influence the studied parameters, as
previously published [13]. Simultaneous exposure to
perinatal hypoxia and iNO, however, significantly reduced
heart weight, the heart to body ratio, and RV weight
compared to mice born in normoxia or hypoxia alone. The
LV+ S weight was also decreased in mice exposed to hypoxia
plus iNO compared to controls. Finally, the RV/(LV + S)
ratio seemed lower in mice exposed to hypoxia and iNO
than in controls or mice with perinatal hypoxia, but the
difference was not quite significant between mice born in
hypoxia in the presence or absence of iNO (𝑃 = 0.0677,
using the Mann-Whitney test), as well as between mice born
in hypoxia plus iNO and controls (𝑃 = 0.0967, using the
Mann-Whitney test).
In old females (12–15-month-old mice), anatomical data
were similar between mice exposed to perinatal hypoxia
and controls, except for the RV/(LV + S) ratio, which
was significantly higher in mice born in hypoxia than in
controls. Old females submitted to simultaneous exposure
to perinatal hypoxia and iNO displayed similar anatomical
data to controls. However, RV weight and the RV/(LV + S)
ratio were significantly reduced compared to mice exposed
to perinatal hypoxia alone.
3.3. Isolated Pulmonary Artery Reactivity. Pharmacological
response to cumulative doses of the endothelium-dependent
relaxing agent acetylcholine (ACh) was tested in isolated
PA preconstricted with phenylephrine (Figure 2). We previ-
ously showed that ACh-induced relaxation was dramatically
reduced in isolated PA from adult females born in hypoxia
compared to controls [13]. In contrast, isolated PA from
adult mice exposed simultaneously to hypoxia and iNO in
the perinatal period displayed a dose-dependent relaxant
response to ACh, which was similar to controls. Therefore,
ACh-induced relaxation was significantly increased in mice
exposed to perinatal hypoxia plus iNO compared to perinatal
hypoxia alone (Figure 2).
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Figure 2: Pharmacological response of isolated pulmonary arteries
to the endothelium-dependent agent acetylcholine. Dose-response
to acetylcholine (ACh) was tested in pulmonary arteries precon-
stricted with phenylephrine (10−5M), isolated from adult mice born
in normoxia (Ctr), in hypoxia (PH), or in hypoxiawith simultaneous
administration of iNO (PH + NO). Results are expressed as mean ±
SEM of percentage of change in tension induced by the vasodilator
(𝑛 = 6–9 mice). ∗Significant difference compared to controls and
†significant difference between mice exposed to perinatal hypoxia
and iNO and mice with perinatal hypoxia alone (𝑃 < 0.05, two-way
ANOVA). Results obtained with pulmonary arteries of mice born in
normoxia (Ctr) or in hypoxia (PH) were previously published [13].
3.4. eNOS Protein Content. We previously showed that the
eNOS protein relative content was significantly reduced in
the main PA of adult females born in hypoxia compared
to controls [13] (Figure 3(a)). In contrast, the eNOS protein
relative content in PA of adult females exposed simultane-
ously to perinatal hypoxia and iNO was similar to controls
(Figure 3(b)).
4. Discussion
We previously demonstrated, in a murine model of perinatal
hypoxia, that a transient exposure to hypoxia during a critical
period of development induced long-term adverse effects on
the adult pulmonary circulation [13, 27, 29].
In the present study, we investigated in the same experi-
mental model whether iNO administration during the whole
exposure to perinatal hypoxia could have beneficial effects on
the adult pulmonary circulation. Potential protective effects
of iNO were tested by measurement of several parameters
which were found to be altered in adult females exposed to
perinatal hypoxia [13].
In our previous report [13], we demonstrated that peri-
natal hypoxia induced a marked decrease in endothelium-
dependent ACh-induced relaxation of PA, whereas no dif-
ference was found in the relaxation induced by gaseous
NO or NO donors. As the present study aimed to inves-
tigate potential protective effects of iNO against adverse
effects of perinatal hypoxia, the functional experiments
were therefore limited to the pharmacological response of
isolated PA to ACh, which was altered in adult mice exposed
to perinatal hypoxia alone compared to controls, whereas
relaxation induced by the NO donor 2-(N,N-diethylamino)-
diazenolate-2-oxide (DEA/NO) was similar in mice born in
hypoxia and controls.
Vascular reactivity studies showed that although ACh-
induced relaxation was significantly reduced in isolated PA
from adult females exposed to perinatal hypoxia compared
to controls, simultaneous administration of iNO during peri-
natal hypoxic exposure completely restored the vasorelaxant
response to ACh.
Similarly, perinatal exposure to hypoxia with concomi-
tant iNO treatment allowed a total recovery in eNOS protein
content in the main PA of adult females, whereas eNOS
protein expression was shown to be reduced by almost 40%
in adult females born in hypoxia compared to controls [13].
Anatomical data recorded in young adult mice (5-6
months) were similar between females born in hypoxic
conditions and controls. Although previous hemodynamic
studies showed a higher right ventricular pressure in 5-
month-old mice exposed to perinatal hypoxia compared to
controls [13], strongly suggesting a higher resistance state in
the pulmonary circulation, the RV/(LV + S) ratio was not
significantly increased in young adult females. The RV/(LV +
S) ratio was used as an index of right ventricular hypertrophy,
which is a direct consequence of increased pulmonary vascu-
lar resistances accompanying pulmonary hypertension. Here
we showed that, in old females (12–15 months), the RV/(LV+
S) ratio was significantly higher in mice born in hypoxia than
in controls, suggesting that perinatal hypoxia resulted in right
ventricular hypertrophy later in life, probably as a result of
increased pulmonary vascular resistances following perinatal
exposure to hypoxia. Inhaled NO treatment during perinatal
hypoxia significantly reduced RV weight compared to mice
exposed to perinatal hypoxia alone, both in young and old
females. In old females exposed to perinatal hypoxia and
iNO, the RV/(LV + S) ratio was also significantly decreased
compared to mice born in hypoxia alone and thus became
similar to the RV/(LV + S) ratio observed in controls.
Taken together our results suggest that concomitant
administration of iNO during the whole exposure to peri-
natal hypoxia exerts a protective effect on the pulmonary
circulation. Such results argue in favor of a potential long-
term beneficial effect of neonatal iNO therapy. It will be nev-
ertheless necessary to investigate whether neonatal (instead
of perinatal) treatment would confer the same protection
and whether this protective effect could also be observed
on additional parameters, like right ventricular pressure,
sensitivity to acute hypoxia, and molecular components of
the NO/cGMP pathway, such as muscarinic receptors and
phosphodiesterases, which were found to be altered in adult
females exposed to perinatal hypoxia [13].
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Figure 3: Western blotting analysis of eNOS protein expression in pulmonary arteries. (a) Western blotting analysis of eNOS protein relative
content was performed in pulmonary arteries extracts (𝑛 = 3 pools of 10 PA) of adult females born in normoxia (Ctr) or in hypoxia (PH).
These data were previously published in [13]. ∗Significant difference between Ctr and PH groups (𝑃 < 0.05 using unpaired 𝑡-test). (b) Relative
eNOS protein content was analyzed in pulmonary arteries extracts of adultmice born in normoxia (Ctr) or exposed simultaneously to hypoxia
and iNO in the perinatal period (PH + NO) (𝑛 = 4 mice). Results are expressed as mean ± SEM of the relative eNOS protein content after
normalization by 𝛽-actin protein content.
Beneficial effects of iNO were also shown in other exper-
imental models. For example, a 10-day treatment with iNO
(10 ppm) during recovery from a 10-day exposure to neonatal
hypoxia restored lung structure in eNOS-deficient mice, by
stimulation of alveolar and vascular growth [31]. Similarly,
concomitant exposure of 9-day-old rat pups to iNO (20 ppm)
and hypoxia during 14 days attenuated pulmonary vascular
structural changes, right ventricular hypertrophy, and growth
retardation induced by exposure to neonatal hypoxia alone
[32]. In a model of bleomycin-induced bronchopulmonary
dysplasia in neonatal rats, iNO treatment improved lung
structure and prevented right ventricular hypertrophy and
pulmonary vascular remodeling [33]. In adult rats, continu-
ous inhalation ofNO (10 ppm) during a 2-week chronic expo-
sure to hypoxia also reduced pulmonary vascular remodeling
and right ventricular hypertrophy compared to rats exposed
to hypoxia alone [34]. These reports pointed however mainly
to protective effects of iNO against structural pulmonary
alterations resulting from hypoxic exposure. More recently,
inhalation of NO was found to have cardioprotective effects
in murine models of cardiac ischemia-reperfusion injury
[35] and to improve outcomes after cardiac arrest and
successful cardiopulmonary resuscitation in adult mice [36],
even in eNOS-deficient mice [37].The latter protective effects
required the presence of soluble guanylyl cyclase [35, 36].
However, all these studies showed short-term protective
effects of iNO administration, whereas our data demon-
strate long-lasting beneficial effects of perinatal iNO therapy
on the pulmonary circulation throughout life. Indeed, in
our experimental model, perinatal iNO administration was
able to prevent not only the impairment of endothelium-
dependent relaxation in young adults secondary to a perinatal
exposure to hypoxia, but also progressive development of
right ventricular hypertension in old mice.
The mechanisms implicated in the observed protective
effects of iNO treatment during the whole exposure to
perinatal hypoxia remain to be elucidated. It will be first
necessary to distinguish whether protective effects aremainly
due to prenatal or postnatal treatment with iNO.
Prenatal treatment with iNO probably mainly acts
through reduction of pulmonary vascular resistances in
pregnant mice. Indeed, closed-chest hemodynamic studies
showed that acute exposure to iNO in hypoxic conditions was
able to reverse hypoxia-induced increase in right ventricular
pressure in anaesthetized adult mice (unpublished data). Due
to the short half-life of gaseousNO,maternal exposure to iNO
during hypoxia may not directly influence the fetal circula-
tion, although therewas recent evidence that extrapulmonary
effects of iNO could be mediated, in addition to diffusion,
by conversion of iNO into S-nitrosothiols further exported
into the circulation by the type L amino acid transporter [38].
However, improvement of maternal pulmonary circulation,
by reversing hypoxic pulmonary vasoconstriction, could
enhance fetal oxygen delivery and perhaps also improve
fetal growth. Indeed, placental insufficiency, a pathology
associated with decreased nutrients and oxygen supply to the
fetus, results in intrauterine growth restriction.
In our murine model of perinatal hypoxia, body weight
measured in 5-day-old pups was decreased by about 10%
after perinatal hypoxia compared to normoxia. Body weight
in pups exposed to perinatal hypoxia plus iNO was also
significantly reduced compared to controls and did not
significantly differ from pups with perinatal hypoxia alone.
This suggests that maternal exposure to iNO did not pre-
vent growth restriction resulting from perinatal hypoxia.
Therefore neonatal exposure to iNOduring perinatal hypoxia
probably contributes largely to the protective effects of iNO
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against adverse effects of perinatal hypoxia on the adult
pulmonary circulation.
Beneficial effects of neonatal iNO therapy could be
explained by direct effect on the pulmonary circulation
of pups exposed to hypoxia, thanks to the vasorelaxant
properties of iNO allowing the counteraction of pulmonary
vasoconstriction induced by hypoxia. Moreover, if prenatal
exposure to hypoxia induced altered eNOS protein expres-
sion, exogenous NO could also act by compensation for
endogenous NO production deficiency, allowing recovery
of NO-mediated relaxation in pups, thus preventing further
alterations in pulmonary vascular tone regulation. Such
protective effects could be due to prevention of epigenetic
modifications in pulmonary vessels leading to long-term
alterations in the regulation of pulmonary circulation. In
this line, it would be particularly of interest to investigate
whether iNO could prevent the imbalance in the NO/cGMP
pathway in adult pulmonary vasculature following perinatal
hypoxia, with particular attention to muscarinic receptors
and phosphodiesterases. Such a result would suggest that
an appropriate intervention to counteract adverse effects
of a hypoxic insult at a critical period of development
could prevent long-term adverse effects of hypoxia on adult
pulmonary circulation.
It remains therefore to test whether a neonatal iNO
treatment, introduced from birth to the end of the 10-
day perinatal exposure to hypoxia, will be able to exert
similar protective effects against adverse effects of perinatal
hypoxia on the adult pulmonary circulation in our murine
experimental model.
It will be also necessary to confirm such observations
in humans. Indeed, iNO therapy was introduced about 15
years ago to treat neonates with PPHN. However there is
no data on the long-term effects of iNO on the regulation
of adult pulmonary circulation in humans. For example, it
was shown that young adults having recovered from PPHN
before introduction of the iNO therapy (children admitted to
the neonatal-care unit of the Lausanne University Hospital
for Children between 1972 and 1979) displayed exaggerated
pulmonary vasoconstrictive response following reexposure
to hypoxia, namely, during high-altitude exposure [7]. It
will be therefore interesting to investigate whether such aug-
mented pulmonary hypertensive response to hypoxia could
be prevented in young adults having suffered from PPHN
treated with iNO in the neonatal period. Potential long-
term beneficial effects, besides the short-term prognostic
improvement, will be useful indications for neonatologists to
assess the safety of the applied therapy.
In terms of basic research, our data may contribute to
a better understanding of the regulatory mechanisms of the
pulmonary circulation in the adult following a perinatal
hypoxic exposure with or without iNO therapy. In terms of
clinical implications, our studies may help to devise novel
therapeutic strategies to prevent and treat adult pulmonary
vascular disorders secondary to perinatal hypoxic events.
More generally, such results should stimulate researchers
to further investigate cellular and molecular mechanisms
implicated in fetal programming of adult diseases in order
to design novel targeted early therapeutic interventions to
prevent long-term adverse effects of perinatal insults.
It should be noted that most results of the present study
are related to the main PA. The overall reactivity differs
between the large conduit PA and the more distal resistant
pulmonary vessels. The total pulmonary vascular resistance
depends on the combination of the reactivity of all these
vessels, amongwhich large pulmonary arteries have also been
shown to play a role [39, 40]. However, the modifications
observed in themainPAofmice born in hypoxia compared to
controls were already significant. Therefore other alterations
could be expected inmore distal vessels. In our previous study
[13], we displayed that alterations secondary to perinatal
hypoxia were found both in the main PA and at the level
of more distal vessels: molecular assays were performed in
total lung homogenates as well as in PA extracts, to assess
whether molecular changes observed in the main PA were
consistent with changes occurring in total lung. Similarly,
hemodynamic studies indirectly showed the influence of
perinatal hypoxia on distal vessels, which contribute to
the resulting pulmonary arterial pressure, as estimated by
measurement of the right ventricular pressure. In the present
paper, some data, like the prevention of right ventricular
hypertrophy in old mice exposed to perinatal hypoxia, also
suggest that iNO exerts a protective effect against alterations
not only of the main pulmonary artery but also of more distal
vessels.
Moreover, our experimental model was complex, because
it combined pre- and postnatal stimuli. In our previous
studies, the timing of exposure to hypoxia was chosen to
cover the period of lung vasculogenesis, during which the
functional units of gas exchange develop [41]. Further com-
parison between effects of prenatal or postnatal hypoxic insult
would be of interest to better determine the susceptibility
window of the lung vasculature. Moreover, although chronic
hypoxia was found to modulate maternal milk composition
[42], a postnatal exposure to hypoxia will mainly impact
directly the pups, whereas the effects of a prenatal insult
will also depend on the maternal metabolic environment
and body composition. Exposure of pregnant rats or mice
to chronic hypoxia is an established model of intrauterine
growth restriction [43], although the effects vary depending
on oxygen concentration and timing of exposure. Such
experimental models led to reduced pups’ body weight, with
[44] or without [45–47] decrease in litter size compared
to controls. In our murine model or perinatal hypoxia, we
observed a significant reduction in both pups’ body weight
and litter size compared to controls. However, these data were
recorded at the end of the perinatal exposure (at postnatal
day 5), thus resulting from combined pre- and postnatal
insult. Moreover, as food intake is sometimes [45, 47],
but not always [46], reduced in pregnant animals exposed
to hypoxia, such experimental models could introduce a
component of undernutrition. Whether some malnutrition
occurs in our murine model of perinatal hypoxia remains to
be investigated, because maternal weight changes were not
recorded.
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Regarding the timing of iNO treatment, we aimed in
the present study to show whether iNO administration
during the whole exposure to hypoxia could reverse adverse
effects of perinatal hypoxia on adult pulmonary circulation.
Further investigation of potential beneficial effects of separate
prenatal or postnatal treatment would be useful to determine
the therapeutic window in which iNO administration could
provide the greater protective effect. Such information could
help to devise novel targeted therapeutic interventions. Par-
ticular attentionwill be paid to the postnatal treatment, which
is closer to the current clinical practice.
However, despite several limitations, the present paper
points to beneficial effects of perinatal iNO administration
against some adverse effects of perinatal hypoxia on the
adult pulmonary circulation. Further investigations will of
course be necessary to better understand the involved mech-
anisms. However, although several studies displayed short-
termprotective effects of iNOadministration, our data are the
first, to our knowledge, to demonstrate long-lasting beneficial
effects of perinatal iNO therapy on the pulmonary circulation
throughout the life.
5. Conclusions
In the present report, we demonstrated that although a 10-
day exposure to hypoxia in the perinatal period resulted in
alterations of the adult pulmonary circulation, simultaneous
administration of iNOduring thewhole exposure to perinatal
hypoxia completely restored ACh-induced relaxation, as well
as eNOS protein content, in isolated PA of adult females.
Right ventricular hypertrophy observed in old mice born in
hypoxia compared to controls was also prevented by perinatal
iNO treatment. Therefore, concomitant administration of
iNO during perinatal hypoxic exposure seems able to prevent
adverse effects of perinatal hypoxia on the adult pulmonary
circulation.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
This work was supported by the Swiss National Foundation
(Grant number 3200-067046), the Eagle Foundation, the
EmmaMuschamp Foundation, and the FernMoffat Founda-
tion.
References
[1] D. J. P. Barker, “In utero programming of cardiovascular
disease,”Theriogenology, vol. 53, no. 2, pp. 555–574, 2000.
[2] P. D. Gluckman and M. A. Hanson, “Living with the past:
evolution, development, and patterns of disease,” Science, vol.
305, no. 5691, pp. 1733–1736, 2004.
[3] A. L. Fowden, D. A. Giussani, and A. J. Forhead, “Intrauterine
programming of physiological systems: causes and conse-
quences,” Physiology, vol. 21, no. 1, pp. 29–37, 2006.
[4] R. F. Grover, J. H. K. Vogel, G. C. Voigt, and S. G. Blount
Jr., “Reversal of high altitude pulmonary hypertension,” The
American Journal of Cardiology, vol. 18, no. 6, pp. 928–932, 1966.
[5] A. W. Himmelmann, R. Speich, F. Real, and E. W. Russi,
“Unusual course of pulmonary hypertension of vascular origin,”
Respiration, vol. 60, no. 5, pp. 292–294, 1993.
[6] D. O’Neill, R. Morton, and J. A. Kennedy, “Progressive primary
pulmonary hypertension in a patient born at high altitude,”
British Heart Journal, vol. 45, no. 6, pp. 725–728, 1981.
[7] C. Sartori, Y. Allemann, L. Trueb, A. Delabays, P. Nicod, and
U. Scherrer, “Augmented vasoreactivity in adult life associated
with perinatal vascular insult,”The Lancet, vol. 353, no. 9171, pp.
2205–2207, 1999.
[8] F. Sime, D. Pen˜aloza, and L. Ruiz, “Bradycardia, increased
cardiac output, and reversal of pulmonary hypertension in
altitude natives living at sea level,” British Heart Journal, vol. 33,
no. 5, pp. 647–657, 1971.
[9] A. Caslin, D. Heath, and P. Smith, “Influence of hypobaric
hypoxia in infancy on the subsequent development of vasocon-
strictive pulmonary vascular disease in the Wistar albino rat,”
The Journal of Pathology, vol. 163, no. 2, pp. 133–141, 1991.
[10] T. S. Hakim and J. P.Mortola, “Pulmonary vascular resistance in
adult rats exposed to hypoxia in the neonatal period,”Canadian
Journal of Physiology and Pharmacology, vol. 68, no. 3, pp. 419–
424, 1990.
[11] V. Hampl and J. Herget, “Perinatal hypoxia increases hypoxic
pulmonary vasoconstriction in adult rats recovering from
chronic exposure to hypoxia,” American Review of Respiratory
Disease, vol. 142, no. 3, pp. 619–624, 1990.
[12] J. Herget and V. Kukl´ık, “Perinatal lung injury extends in adults
the site of hypoxic pulmonary vasoconstriction upstream.,”
Physiological Research, vol. 44, no. 1, pp. 25–30, 1995.
[13] A. Peyter, V. Muehlethaler, L. Liaudet et al., “Muscarinic
receptor M1 and phosphodiesterase 1 are key determinants in
pulmonary vascular dysfunction following perinatal hypoxia in
mice,” The American Journal of Physiology—Lung Cellular and
Molecular Physiology, vol. 295, no. 1, pp. L201–L213, 2008.
[14] M. A. Heymann, “Control of the pulmonary circulation in
the fetus and during the transitional period to air breathing,”
European Journal of Obstetrics Gynecology and Reproductive
Biology, vol. 84, no. 2, pp. 127–132, 1999.
[15] J. F. Tolsa, “[Physiologic aspects of lung circulation in adjust-
ment to extra-uterine life],”Archives of Pediatrics, vol. 7, supple-
ment 2, pp. 269s–270s, 2000.
[16] P. J. Barnes and S. F. Liu, “Regulation of pulmonary vascular
tone,” Pharmacological Reviews, vol. 47, no. 1, pp. 87–131, 1995.
[17] D. Merkus, V. J. de Beer, B. Houweling, and D. J. Duncker,
“Control of pulmonary vascular tone during exercise in health
and pulmonary hypertension,” Pharmacology andTherapeutics,
vol. 119, no. 3, pp. 242–263, 2008.
[18] S. H. Abman, J. P. Kinsella, T. A. Parker, L. Storme, and T.
D. Le Cras, “Physiologic roles of nitric oxide in the perinatal
pulmonary circulation,” in The Fetal and Neonatal Pulmonary
Circulation, E. K. Weir, S. L. Archer, and J. T. Reeves, Eds.,
pp. 239–260, Futura Publishing Company, Armonk, NY, USA,
2000.
[19] M. P. Coggins and K. D. Bloch, “Nitric oxide in the pulmonary
vasculature,” Arteriosclerosis, Thrombosis, and Vascular Biology,
vol. 27, no. 9, pp. 1877–1885, 2007.
[20] M. C. Walsh-Sukys, J. E. Tyson, L. L. Wright et al., “Persistent
pulmonary hypertension of the newborn in the era before nitric
BioMed Research International 9
oxide: practice variation and outcomes,” Pediatrics, vol. 105, no.
1, pp. 14–20, 2000.
[21] J. Smith and G. F. Kirsten, “Persistent pulmonary hypertension
of the neonate in a developing country—does extracorporeal
membrane oxygenation have a role to play?” South African
Medical Journal, vol. 83, no. 10, pp. 742–745, 1993.
[22] T. J. Weigel and J. R. Hageman, “National survey of diagnosis
and management of persistent pulmonary hypertension of the
newborn,” Journal of Perinatology, vol. 10, no. 4, pp. 369–375,
1990.
[23] N. F. M. Porta and R. H. Steinhorn, “Pulmonary vasodilator
therapy in the NICU: inhaled nitric oxide, sildenafil, and other
pulmonary vasodilating agents,” Clinics in Perinatology, vol. 39,
no. 1, pp. 149–164, 2012.
[24] J. P. Kinsella and S. H. Abman, “Inhaled nitric oxide: current
and future uses in neonates,” Seminars in Perinatology, vol. 24,
no. 6, pp. 387–395, 2000.
[25] O. Okada, N. Tanabe, J. Yasuda et al., “Prediction of life
expectancy in patients with primary pulmonary hypertension.
A retrospective nationwide survey from 1980–1990,” Internal
Medicine, vol. 38, no. 1, pp. 12–16, 1999.
[26] W. D. Rosenblum, “Pulmonary arterial hypertension: pathobi-
ology, diagnosis, treatment, and emerging therapies,” Cardiol-
ogy in Review, vol. 18, no. 2, pp. 58–63, 2010.
[27] M. Marino, J. L. Be´ny, A. C. Peyter, R. Bychkov, G. Diaceri, and
J. F. Tolsa, “Perinatal hypoxia triggers alterations in K+ channels
of adult pulmonary artery smooth muscle cells,”The American
Journal of Physiology: Lung Cellular and Molecular Physiology,
vol. 293, no. 5, pp. L1171–L1182, 2007.
[28] J. Tolsa, M. Marino, A. Peyter, and J. Beny, “Role of mem-
brane potential in endothelium-dependent relaxation of iso-
lated mouse main pulmonary artery,” Journal of Cardiovascular
Pharmacology, vol. 47, no. 4, pp. 501–507, 2006.
[29] M.Marino, J. Be´ny, A. Peyter, G. Diaceri, and J. Tolsa, “Perinatal
hypoxia enhances cyclic adenosine monophosphate-mediated
BKCa channel activation in adult murine pulmonary artery,”
Journal of Cardiovascular Pharmacology, vol. 57, no. 2, pp. 154–
165, 2011.
[30] J. Tolsa, Y. Gao, F. C. Sander, A. Souici, A. Moessinger, and
J. Usha Raj, “Differential responses of newborn pulmonary
arteries and veins to atrial and C-type natriuretic peptides,”
American Journal of Physiology. Heart and Circulatory Physiol-
ogy, vol. 282, no. 1, pp. H273–H280, 2002.
[31] V. Balasubramaniam, A. M. Maxey, D. B. Morgan, N. E.
Markham, and S. H. Abman, “Inhaled NO restores lung struc-
ture in eNOS-deficientmice recovering fromneonatal hypoxia,”
American Journal of Physiology: Lung Cellular and Molecular
Physiology, vol. 291, no. 1, pp. L119–L127, 2006.
[32] J. D. Roberts Jr., C. T. Roberts, R. C. Jones, W. M. Zapol,
and K. D. Bloch, “Continuous nitric oxide inhalation reduces
pulmonary arterial structural changes, right ventricular hyper-
trophy, and growth retardation in the hypoxic newborn rat,”
Circulation Research, vol. 76, no. 2, pp. 215–222, 1995.
[33] P. Tourneux, N. Markham, G. Seedorf, V. Balasubramaniam,
and S. H. Abman, “Inhaled nitric oxide improves lung structure
and pulmonary hypertension in a model of bleomycin-induced
bronchopulmonary dysplasia in neonatal rats,” American Jour-
nal of Physiology—Lung Cellular and Molecular Physiology, vol.
297, no. 6, pp. L1103–L1111, 2009.
[34] C. Kouyoumdjian, S. Adnot, M. Levame, S. Eddahibi, H.
Bousbaa, and B. Raffestin, “Continuous inhalation of nitric
oxide protects against development of pulmonary hypertension
in chronically hypoxic rats,”The Journal of Clinical Investigation,
vol. 94, no. 2, pp. 578–584, 1994.
[35] Y. Nagasaka, E. S. Buys, E. Spagnolli et al., “Soluble guanylate
cyclase-𝛼1 is required for the cardioprotective effects of inhaled
nitric oxide,” The American Journal of Physiology: Heart and
Circulatory Physiology, vol. 300, no. 4, pp. H1477–H1483, 2011.
[36] S. Minamishima, K. Kida, K. Tokuda et al., “Inhaled nitric
oxide improves outcomes after successful cardiopulmonary
resuscitation in mice,” Circulation, vol. 124, no. 15, pp. 1645–
1653, 2011.
[37] K. Kida, K. Shirozu, B. Yu, J. B. Mandeville, K. D. Bloch,
and F. Ichinose, “Beneficial effects of nitric oxide on out-
comes after cardiac arrest and cardiopulmonary resuscitation
in hypothermia-treatedmice,”Anesthesiology, vol. 120, no. 4, pp.
880–889, 2014.
[38] J. A. Torok, M. V. Brahmajothi, H. Zhu, B. T. Tinch, R. L. Auten,
and T. J. McMahon, “Transpulmonary flux of S-nitrosothiols
and pulmonary vasodilation during nitric oxide inhalation role
of transport,” The American Journal of Respiratory Cell and
Molecular Biology, vol. 47, no. 1, pp. 37–43, 2012.
[39] J. Belik, “Large pulmonary arteries and the control of pul-
monary vascular resistance in the newborn,” Canadian Journal
of Physiology and Pharmacology, vol. 72, no. 11, pp. 1464–1468,
1994.
[40] J. Belik, “Myogenic response in large pulmonary arteries and its
ontogenesis,” Pediatric Research, vol. 36, no. 1, part 1, pp. 34–40,
1994.
[41] D. Warburton, M. Schwarz, D. Tefft, G. Flores-Delgado, K. D.
Anderson, and W. V. Cardoso, “The molecular basis of lung
morphogenesis,”Mechanisms of Development, vol. 92, no. 1, pp.
55–81, 2000.
[42] E. D. Bruder, J. van Hoof, J. B. Young, and H. Raff, “Epidermal
growth factor and parathyroid hormone-related peptidemRNA
in the mammary gland and their concentrations in milk:
Effects of postpartum hypoxia in lactating rats,” Hormone and
Metabolic Research, vol. 40, no. 7, pp. 446–453, 2008.
[43] P. M. Vuguin, “Animal models for small for gestational age and
fetal programing of adult disease,” Hormone Research, vol. 68,
no. 3, pp. 113–123, 2007.
[44] S.-T. J. Huang, K. C. T. Vo, D. J. Lyell et al., “Developmental
response to hypoxia,” The FASEB Journal, vol. 18, no. 12, pp.
1348–1365, 2004.
[45] E. J. Camm, J. A. Hansell, A. D. Kane et al., “Partial contribu-
tions of developmental hypoxia and undernutrition to prenatal
alterations in somatic growth and cardiovascular structure and
function,” The American Journal of Obstetrics and Gynecology,
vol. 203, no. 5, pp. 495.e24–495.e34, 2010.
[46] P. J. Tapanainen, P. Bang, K. Wilson, T. G. Unterman, H. J.
Vreman, and R. G. Rosenfeld, “Maternal hypoxia as a model for
intrauterine growth retardation: effects on insulin-like growth
factors and their binding proteins,” Pediatric Research, vol. 36,
no. 2, pp. 152–158, 1994.
[47] T. M. Tomlinson, J. R. Garbow, J. R. Anderson, J. A. Engelbach,
D.M. Nelson, and Y. Sadovsky, “Magnetic resonance imaging of
hypoxic injury to themurine placenta,”TheAmerican Journal of
Physiology—Regulatory Integrative and Comparative Physiology,
vol. 298, no. 2, pp. R312–R319, 2010.
